drug
naloxone hydrochloride
Marketedupdated 5mo agoby Emergent Devices Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval662 co-mentions · 280 sources
- drugSUBOXONE454 co-mentions · 227 sources
- drugBUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE454 co-mentions · 227 sources
- drugSUBLOCADE454 co-mentions · 227 sources
- drugbuprenorphine ER454 co-mentions · 227 sources
- drugbuprenorphine454 co-mentions · 227 sources
- drugBRIXADI454 co-mentions · 227 sources
- drugBUPRENORPHINE HYDROCHLORIDE454 co-mentions · 227 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 4 investigational indications.
all catalysts(15)
approval · 15
Jul 11, 2001
approval
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE (NALOXONE HYDROCHLORIDE) — FDA approval
naloxone hydrochloride
→
Jan 7, 2015
approval
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE (NALOXONE HYDROCHLORIDE) — FDA approval
naloxone hydrochloride
→
Apr 20, 2017
approval
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE (NALOXONE HYDROCHLORIDE) — FDA approval
naloxone hydrochloride
→
Apr 20, 2017
approval
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE (NALOXONE HYDROCHLORIDE) — FDA approval
naloxone hydrochloride
→
Sep 18, 2018
approval
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE (NALOXONE HYDROCHLORIDE) — FDA approval
naloxone hydrochloride
→
Sep 20, 2018
approval
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE (NALOXONE HYDROCHLORIDE) — FDA approval
naloxone hydrochloride
→
Oct 9, 2019
approval
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE (NALOXONE HYDROCHLORIDE) — FDA approval
naloxone hydrochloride
→
Mar 4, 2021
approval
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE (NALOXONE HYDROCHLORIDE) — FDA approval
naloxone hydrochloride
→
Jan 3, 2024
approval
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE (NALOXONE HYDROCHLORIDE) — FDA approval
naloxone hydrochloride
→
Jan 3, 2024
approval
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE (NALOXONE HYDROCHLORIDE) — FDA approval
naloxone hydrochloride
→
Apr 19, 2024
approval
$SCNX0.3314-4.08%
REZENOPY (NALOXONE HYDROCHLORIDE) — FDA approval
naloxone hydrochloride
→
Oct 31, 2024
approval
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE (NALOXONE HYDROCHLORIDE) — FDA approval
naloxone hydrochloride
→
Jan 23, 2026
approval
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE (NALOXONE HYDROCHLORIDE) — FDA approval
naloxone hydrochloride
→
Jan 23, 2026
approval
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE (NALOXONE HYDROCHLORIDE) — FDA approval
naloxone hydrochloride
→
Apr 9, 2026
approval
$SCNX0.3314-4.08%
REZENOPY (NALOXONE HYDROCHLORIDE) — FDA approval
naloxone hydrochloride
→
Trials studying naloxone hydrochloride
- phase1Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults
- phase2A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone Blockade
- phase1Pharmacodynamic Evaluation of Intranasal Nalmefene
- phase4A Phase 4 Clinical Study to Investigate the Efficacy and Safety of Naloxone HCI IV in Patients With Stroke
- phase4Clinical Outcomes From Nalmefene
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 12, 2026
73 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (61)
- Jun 14, 2041formulationUS 11571518
- Feb 5, 2041method-of-use (U-4397)US 12514854
- May 24, 2039formulationUS 11027072
- Mar 20, 2035formulationUS 10220158
- Mar 20, 2035formulationUS 10220158
- Aug 26, 2034formulationUS 10722510
- Aug 26, 2034formulationUS 10973814
- Aug 26, 2034formulationUS 11135155
- Aug 26, 2034formulationUS 11617713
- Aug 26, 2034formulationUS 11628139
- Aug 26, 2034formulationUS 11975096
- Aug 26, 2034formulationUS 12414915
- Jul 18, 2034formulationUS 9517307
- Jul 18, 2034formulationUS 9517307
- May 11, 2032method-of-use (U-3671)US 11020343
- May 11, 2032formulationUS 11806428
- May 11, 2032method-of-use (U-3671)US 12458591
- Feb 4, 2032formulationUS 8627816
- Feb 4, 2032formulationUS 8627816
- May 24, 2031method-of-use (U-2476)US 101437924.6y
- May 24, 2031method-of-use (U-2476)US 101437924.6y
- May 24, 2031method-of-use (U-2476)US 101439724.6y
- Feb 28, 2031method-of-use (U-1907)US 103222394.4y
- Feb 28, 2031method-of-use (U-1907)US 103222394.4y
- Feb 28, 2031method-of-use (U-1907)US 103222394.4y
- Feb 28, 2031formulationUS 89399434.4y
- Feb 28, 2031formulationUS 89399434.4y
- Feb 28, 2031formulationUS 89399434.4y
- Feb 28, 2031formulationUS 90220224.4y
- Feb 28, 2031formulationUS 90220224.4y
- Feb 28, 2031formulationUS 90220224.4y
- Feb 28, 2031formulationUS 94748694.4y
- Feb 28, 2031formulationUS 94748694.4y
- Feb 28, 2031formulationUS 94748694.4y
- Feb 28, 2031formulationUS 98148384.4y
- Nov 2, 2029formulationUS 80213443.1y
- Nov 2, 2029formulationUS 80213443.1y
- Apr 10, 2029formulationUS 82266102.5y
- Apr 10, 2029formulationUS 82266102.5y
- Nov 25, 2028formulationUS 82315732.2y
- Nov 25, 2028formulationUS 82315732.2y
- Oct 30, 2028formulationUS 77491942.1y
- Oct 30, 2028formulationUS 77491942.1y
- Mar 12, 2028formulationUS 79470171.4y
- Mar 12, 2028formulationUS 79470171.4y
- May 23, 2027formulationUS 9724471235d
- May 23, 2027formulationUS 9724471235d
- Feb 27, 2027formulationUS 8206360150d
- Feb 27, 2027formulationUS 8206360150d
- Feb 20, 2027formulationUS 9238108143d
- Feb 20, 2027formulationUS 9238108143d
- Dec 12, 2026formulationUS 1159028673d
- Dec 12, 2026formulationUS 1159028673d
- Jun 25, 2026formulationUS 10960155
- Jun 25, 2026formulationUS 10960155
- Jun 10, 2026formulationUS 7731686
- Jun 1, 2026formulationUS 7731686
- Mar 31, 2026formulationUS 8926594
- Mar 31, 2026formulationUS 8926594
- Feb 1, 2026formulationUS 9278182
- Feb 1, 2026formulationUS 9278182
FDA exclusivities (2)
- Apr 19, 2027NPNP201d
- Mar 7, 2026NPNP
News(6)
- Goa Therapeutics launches with ‘immeasurably huge’ vision of creating Narcan for alcoholA new biotech has sprung out of stealth with a bold vision to develop the “greatest therapeutic of all time”—a drug that can quickly sober up people who have had too much to drink.fiercebiotech · 12d ago
- Narcan maker Emergent BioSolutions eliminates top R&D role in sweeping restructuringTwo and a half years into his tenure as Emergent BioSolutions CEO, Joseph Papa is executing another round of restructuring to align the business with “current business realities.”fiercebiotech · 1mo ago
- Syphilis spreads while researchers contend with federal constraints and a drug shortageAt the San Diego-Tijuana border, syphilis spreads while researchers contend with federal constraints and a drug shortage.stat · 2mo ago
- Trump administration will bring special ed to HHSInfant mortality rate dips, OTC naloxone options rise, and other health news from Morning Roundsstat · 3mo ago
- FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid OverdoseThe U.S. Food and Drug Administration (FDA) today approved another over-the-counter (OTC) intranasal naloxone product, Rextovy, a 4 milligram (mg) naloxone hydrochloride nasal spray for the emergen…fda_press · 3mo ago
- Are Republicans turning against medications for treating opioid addiction?Federal actions and proposals have reignited debate over methadone and buprenorphine, worrying addiction experts and patient groups.stat · 3mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that